Finasteride for benign prostatic hyperplasia

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 10, 2010, Pages

  Tacklind, James ^a   Fink, Howard A ^b   Macdonald, Roderick ^b   Rutks, Indy ^b   Wilt, Timothy J ^b  

^a Independent contractor   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO; TAMSULOSIN; TERAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; ENZYME INHIBITOR; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MICTURITION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGICAL APPROACH; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE RETENTION; DRUG COMBINATION; META ANALYSIS; METHODOLOGY; PROSTATISM;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; DISEASE PROGRESSION; DOXAZOSIN; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79551622371     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006015.pub3     Document Type: Review

References (82)

1. Abrams P, Schafer W, Tammela TLJ, Barrett DM, Hedlund H, Rollema HJ, et al. Improvement of pressure flow parameters with finasteride is greater in men with large prostates. The Journal of Urology 1999;161(5):1513-7.
2. Agrawal MS, Aron M. Prospective double-blind randomized controlled trial of terazosin, finasteride and allylestrenol in the management of benign prostatic hyperplasia. Indian Journal of Urology [serial online] 2001 [cited 2010 Mar 4]; Vol. 17, issue 2:132-40. Available from: http://www.indianjurol.com/text.asp$2001/17/2/132/21043.
3. Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K, and The Scandinavian BPH Study Group. Can Finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995;46(5):631-7.
4. Beisland HO, Binkowitz B, Brekkan E, Ekman P, Kontturi M, Letonen T, et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. European Urology 1992;22:271-7.
5. Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY on behalf of the CUSP investigators. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community-based study. Clinical Therapeutics 1995;17(5):956-69.
6. Carraro J-C, Raynaud J-P, Koch G, Chisholm GD, Di Silverio F, Teillac P, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1, 098 patients. The Prostate 1996;29:231-40.
7. The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Prostate 1993;22:291-9.
8. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The New England Journal of Medicine 1992;327(17):1185-91.
9. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, and Grossman EB for the PREDICT Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-26.
10. Lee E. Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients. The Journal of International Medical Research 2002;30:584-90.
11. Johnson, II TM, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. The Journal of Urology 2003;170:145-8.
12. Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs Cooperative Study. The Journal of Urology 2000;163:1134-7.
13. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ, for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both n benign prostatic hyperplasia. The New England Journal of Medicine 1996;335(8):533-9.
14. Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Journal of Urology 1998;160(4):1358-67.
15. Marberger MJ, on behalf of the PROWESS Study Group. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. Urology 1998;51:677-86.
16. Marks LS, Partin AW, Gormley GJ, Dorey FJ, Shery ED, Garris JB, et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. The Journal of Urology 1997;157(6):2171-8.
17. Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, et al. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. Urology 2000;56:610-6.
18. Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, Mobley D, Narayan P, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001;57:1073-7.
19. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New England Journal of Medicine 1998;338(9):557-63.
20. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003;61:579-84.
21. Johnson, II TM, Burrows PK, Kusek JW, Nyberg LM, Tenover JL, Lepor H, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. The Journal of Urology 2007;178:2045-51.
22. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater. The Journal of Urology 2006;175:217-21.
23. McConnell JD, Roehrborn CG, Bautista OM, Andriole, Jr GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The New England Journal of Medicine 2003;349(25):2387-98.
24. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault J-P, Afridi SK, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Canadian Medical Association Journal 1996;155(9):1251-9.
25. Polat O, Ozbey I, Gu;l O, Demirel A, Bayraktar Y. Pharmacotherapy of benign prostatic hyperplasia: inhibitor of 5 Alpha-reductase. International Urology and Nephrology 1997;293(3):323-30.
26. Rigatti P, Brausi M, Scarpa RM, Porru D, Schumacher H, and Rizzi CA for the MICTUS Study Group. A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases 2003;6:315-23.
27. Sökeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. British Journal of Urology International 2000;86:439-42.
28. Tammela TLJ, Kontturi MJ. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. The Journal of Urology 1993;149:342-4.
29. Tempany CMC, Partin AW, Zerhouni EA, Zinreich SJ, Walsh PC. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. The Prostate 1993;22:39-42.
30. Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA, on behalf of the Primary Care Investigator Study Group. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Clinical Therapeutics 1997;19(2):243-58.
31. Yu H-J, Chiu T-Y, Lai M-K. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial. Journal of the Formosan Medical Association 1995;94(1/2):37-41.
32. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology 1998;52:195-202.
33. Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001;58:203-9.
34. Bruskewitz R, Girman CJ. Effect of finasteride on bother and health-related quality of life associated with benign prostatic hyperplasia. The Journal of Urology 1999;161(4S Supplement):268.
35. Ekman P. Endocrine therapy for benign prostatic hyperplasia. Journal d'Urologie 1995;101(1):22-5.
36. Ekman P, Andersen JT, Wolf H. Finasteride in the treatment of benign prostatic hyperplasia. Acta Urologica Belgica 1996;64(1):IX-XII.
37. Geller J. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. European Urology 1995;27:267-73.
38. Girman CJ, Kolman C, Liss CL, Bolognese JA, Binkowitz BS, Stoner E, Finasteride Study Group. Effects of finasteride on the health-related quality of life in men with symptomatic benign prostatic hyperplasia. The Prostate 1996;29:83-90.
39. Gormley GJ, Stoner E. Clinical results with finasteride. Progress in Clinical and Biological Research 1994;386:205-7.
40. Grino PB, Bruskewitz R, Blaivas JG, Siroky MB, Andersen JT, Cook T, Stoner E. Maximum urinary flow rate by uroflowmetry: automatic or visual interpretation. The Journal of Urology 1993;149:339-41.
41. Grino P, Stoner E, and the Finasteride Study Group. Finasteride for the treatment and control of benign prostatic hyperplasia: summary of Phase III controlled studies. European Urology 1994;25(suppl 1):24-8.
42. Jeong YB, Kwon KS, Kim SD, Kim HJ. Effect of discontinuation of 5a-reductase inhibitors on prostate volume and symptoms in men with BPH: A prospective study. Urology 2009;73:802-6.
43. Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, et al. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. Urology 2000;56:610-6.
44. Kaplan SA, Roehrborn CG, McConnell JD, Meehan AG, Surynawanshi S, Lee JY, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS Trial. The Journal of Urology 2008;180:1030-3.
45. Kirby RS, Bryan J, Eardley I, Christmas TJ, Liu S, Holmes SAV, et al. Finasteride in the treatment of benign prostatic hyperplasia. A dynamic evaluation. British Journal of Urology 1992;70:65-72.
46. Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003;61:354-58.
47. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003;61:791-6.
48. Marberger MJ, Andersen JT, Nickel JC, Malice M-P, Gabriel M, Pappas F, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. European Urology 2000;38:563-8.
49. Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999;53:574-80.
50. Moore E, Bracken B, Bremner W, Geller J, Imperato-McGinley J, McConnell J, et al. Proscar® Five-year experience. European Urology 1995;28:304-9.
51. Nacey JN, Mefan PJ, Delahunt B. The effect of finasteride on prostate volume, urinary flow and symptom score in men with benign prostatic hyperplasia. Australia New Zealand Journal of Surgery 1995;65:35-9.
52. Paick SH, Meehan A, Lee M, Penson DF, Wessells H. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the PROSCAR long-term efficacy and safety study. The Journal of Urology 2005;173:903-7.
53. Perimenis P, Gyftopoulos K, Markou S, Barbalias G. Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. Urology 2002;59:373-7.
54. Roehrborn CG, Bruskewitz R, Nickel GC, Glickman S, Cox II C, Anderson R, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. European Urology 2000;37:528-36.
55. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. The Journal of Urology 2000;163:13-20.
56. Roehrborn CG, McConnell JD, Saltzman B, Bergner D, Gray T, Narayan P, et al. Storage (irritative) and voiding (obstructive) symptoms predictors of benign prostatic hyperplasia progression and related outcomes. European Urology 2002;42:1-6.
57. Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. The Journal of Urology 2004;171:1194-8.
58. Schäfer W, Tammela TLJ, Barrett DM, Abrams P, Hedlund H, Rollema HJ, et al. Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Urology 1999;54:278-83.
59. Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design. Contemporary Clinical Trials 2007;28:770-9.
60. Stoner E, Finasteride Study Group. The clinical effects of 5a-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Journal of Urology 1992;47:1298-1302.
61. Stoner E, members of the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43(3):284-94.
62. Stoner E, and the Finasteride Study Group. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Archives of Internal Medicine 1994;154:83-8.
63. Tammela TLJ, Kontturi MJ. Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. The Journal of Urology 1995;154:1466-9.
64. Tewari A, Shinohara K, Narayan P. Transition zone volume and transition zone ratio: predictor or uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology 1995;45(2):258-65.
65. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. The New England Journal of Medicine 2003;349(3):215-24.
66. Vaughan D, Imperato-McGinley J, McConnell J, Matsumoto AM, Bracken B, Roy J, et al. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 2002;60:1040-4.
67. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, Lepor H. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology 1995;154(5):1770-5.
68. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. The Journal of Urology 1984;132:474-9.
69. Bonilla J, Stoner E, Grino P, Binkowitz B, Taylor A. Intra- and interobserver variability of MRI prostate volume measurements. The Prostate 1997;31:98-102.
70. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48:398-405.
71. Byrnes CA, Liss CL, Tenover JL, Lippert MC, Gillenwater JY. Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases 1997;1:26-31.
72. Roehrborn CG, McConnell JD. Chapter 86-Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. In: Kavoussi LR, Novick AC, Partin AW, Peters CA editor(s). Campbell-Walsh Urology. 9. Vol. 3, Philadelphia: Saunders Elsevier, 2007.
73. Higgins JPT, Green S, editors. Rationale for concern about bias. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. www.cochrane.org/resources/handbook/hbook.htm (accessed 17 February 2009).
74. Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: A systematic review of randomised trials. BMC Urology 2002;2(14):17 pages. [PUBMED: 12477383]
75. García-Perdomo HA, Lopez HE, Tacklind J. 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database of Systematic Reviews 2015, Issue 11. [DOI: 10.1002/14651858.CD011928]
76. GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal 2004;328:1-8.
77. Wei JT, Calhoun EA, Jacobsen SJ. Benign prostatic hyperplasia. In: Litwin MS, Saigal CS editor(s). Urologic Diseases of America. Washington, DC: US Government Publishing Office, 2007:45-69.
78. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP Journal Club 1995;123(3):A12-3.
79. Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. Journal of Affective Disorders 2009;118:1-8.
80. Roehrborn CG. Meta-analysis of randomized clinical trials of finasteride. Urology 1998;51(Suppl 4A):46-9.
81. Stoner E, Finasteride Study Group. The clinical effects of 5a-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Journal of Urology 1992;47:1298-1302.
82. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003;61:579-84.